DOP061 Phase III randomised, double-blind, controlled trial...

Journal of Crohn's and Colitis 2017 / 02 Vol. 11; Iss. suppl_1

DOP061 Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results

Kim, Y.H., Ye, B.D., Pesegova, M., Alexeeva, O., Osipenko, M., Lahat, A., Dorofeyev, A., Salamon, A., Fishman, S., Levchenko, O., Cheon, J.H., Scribano, M.L., Mateescu, R.-B., Lee, K.M., Eun, C.S., Le
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
11
Language:
english
Journal:
Journal of Crohn's and Colitis
DOI:
10.1093/ecco-jcc/jjx002.098
Date:
February, 2017
File:
PDF, 78 KB
english, 2017
Conversion to is in progress
Conversion to is failed